Clinical Trial Detail

NCT ID NCT01610284
Title Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + BKM120

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST